Roberta Bartolucci

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer

Rafael Rosell, Marcin Skrzypski, Ewa Jassem et al. · PLoS ONE · 2007 · 211 citations · Full text

Medicine, Molecular Biology, Oncology +17

Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study

Cesare Gridelli, Franco Perrone, Ciro Gallo et al. · European Journal of Cancer · 1997 · 95 citations

Medicine, Oncology, Pharmacology +7

Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research.

Giorgio Cocconi, Giancarlo Bisagni, M. Bacchi et al. · Journal of Clinical Oncology · 1991 · 62 citations

Medicine, Oncology, Pharmacology +17